Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€35.78

€35.78

-2.610%
-0.97
-2.610%
€49.33
 
07.06.24 / Tradegate WKN: 870353 / Symbol: STAA / Name: STAAR Surgical / Stock / Healthcare Equipment & Supplies / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Staar Surgical Co. Stock

A loss of -2.610% shows a downward development for Staar Surgical Co..
We see a rather positive sentiment for Staar Surgical Co. with 12 Buy predictions and 1 Sell predictions.
As a result the target price of 49 € shows a positive potential of 36.95% compared to the current price of 35.78 € for Staar Surgical Co..

Pros and Cons of Staar Surgical Co. in the next few years

Pros
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Staar Surgical Co. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Staar Surgical Co. -2.610% -6.531% -16.186% -25.845% 23.252% -69.129% -
Orasure Tech 3.770% 2.326% -12.871% -13.725% -40.940% -41.937% -40.605%
scPharmaceuticals 12.900% 13.514% -3.226% -59.615% -26.957% -12.863% -
SI-BONE Inc 2.400% 4.065% -3.030% -50.000% -32.632% -51.145% -

Comments

Prediction Buy
Perf. (%) -11.02%
Target price 51.156
Change
Ends at 08.05.25

STAAR Surgical (NASDAQ: STAA) had its price target raised by analysts at Mizuho from $53.00 to $55.00. They now have a "buy" rating on the stock.
Ratings data for STAA provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -25.58%
Target price 49.327
Change
Ends at 11.04.25

STAAR Surgical (NASDAQ: STAA) had its price target raised by analysts at Mizuho from $45.00 to $53.00. They now have a "buy" rating on the stock.
Ratings data for STAA provided by MarketBeat
Show more

STAAR Surgical (NASDAQ: STAA) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Ratings data for STAA provided by MarketBeat
Show more

News

STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical to Participate in Goldman Sachs 45th Annual Global Healthcare Conference


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites

STAAR Surgical Reports First Quarter 2024 Results: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical Reports First Quarter 2024 Results


STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel: https://mms.businesswire.com/media/20240501408389/en/2115844/5/nate_sisitsky_linkedin.jpg
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today